Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure
Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation(Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure (HF) patients published in the Journal of Cardiac Failure. The results of the study show that Daxor’s BVA-100® provides unique and actionable data that is critical for addressing heart failure in patients.
The Journal of Cardiac Failure is the official peer reviewed journal of the Heart Failure Society of America and the Japanese Heart Failure Society.
The study titled, “Discordance of Pressure and Volume: Potential Implications for Pressure-Guided Remote Monitoring in Heart Failure,” sought to test the relationship (or lack thereof) between a commercially available implantable pulmonary artery pressure (PAP) monitor, estimates of cardiac blood volume, and actual circulating blood volume as determined by Daxor’s technology. The results showed that there is a lack of agreement between PAP and blood volume metrics, confirming that the two variables should be thought of as independent variables for physicians to target.
Marat Fudim, M.D., Department of Medicine, Duke University Hospital, lead author of the study, concluded, “These findings indicate that pressure-based assessment of congestion in ambulatory HF patients does not accurately represent intravascular volume. Nevertheless, pressure changes remain indicative of HF exacerbations and volume-based phenotyping may be required to guide decongestion strategies in patients with HF.”
“There exists a significant need to optimize blood volume for all heart failure patients. This study shows BVA technology uniquely allows insight for clinicians to treat patients to the primary goal of a normal blood volume that neither pressure metrics nor estimates of volume alone allow,” noted Marc Silver, M.D., one of the study’s authors.
“More than 100 published peer-reviewed studies across many medical conditions have proven our BVA-100 blood test provides unique accuracy, efficacy, and value,” said Michael Feldschuh, CEO of Daxor Corporation. “This study is further validation that pressure overload does not always equal volume overload. Our test informs clinicians with critical information to help manage and treat volume derangements in complex HF patients and past studies in peer-reviewed journals have shown substantial improvements in mortality reduction, hospital readmission, and costs from the use of our product.”
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 60,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing multicenter trials in the areas of COVID-19 and heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Sr. Managing Partner, CORE IR